Financial Consulate, Inc Heron Therapeutics, Inc. Transaction History
Financial Consulate, Inc
- $678 Million
- Q3 2025
A detailed history of Financial Consulate, Inc transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Financial Consulate, Inc holds 500 shares of HRTX stock, worth $530. This represents 0.0% of its overall portfolio holdings.
Number of Shares
500Holding current value
$530% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding HRTX
# of Institutions
182Shares Held
132MCall Options Held
1.56MPut Options Held
27.1K-
Rubric Capital Management LP New York, NY26.7MShares$28.3 Million1.27% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.46MShares$8.97 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.33MShares$8.82 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA7.85MShares$8.32 Million0.03% of portfolio
-
Velan Capital Investment Management LP Alpharetta, GA6.99MShares$7.41 Million24.86% of portfolio
About HERON THERAPEUTICS, INC.
- Ticker HRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 118,774,000
- Market Cap $126M
- Description
- Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...